nora volkow md director national institute drug abuse francis collins md phd director national institutes health co authored paper role science current opioid crisis full text article available free online new england journal medicine reference given article authors review scientific interventions three levels care treating opioid addiction use treating preventing overdoses treatment chronic pain treatment chronic non cancer pain cncp opioids realistically viewed precipitant epidemic brief page review good rapid review science behind interventions level cooperation nida nih private industry may surprise people authors point level mortality current epidemic needs approached urgency levels level opioid overdose prevention reversal potent long lasting opioid antagonists developed counter exposure fentanyl carfentanil appearing increasing rate street narcan nasal spray probably effective practical outcome industry nida partnership wearable device detect signals impending overdose administer opioid receptor antagonist mentioned level addiction treatment methadone buprenorphine extended release naltrexone mentioned current treatments opioid use disorder access providers discussed limiting factor vaccines novel receptor approaches discussed potentially new pharmacological approaches problem new approaches chronic pain discussed greater detail cooperation nih industry emphasized terms getting approaches market clinical use concluding section emphasis nih industry partnerships central theme argument makes imminent sense two decades rancorous debate effects pharmaceutical company pizza prescribing level access highest level taxpayer funded research somewhat stunning else might immediately useful i concentrate buprenorphine come couple anyone working compound people addicted opioids routinely encounters problems use common treat people still withdrawal symptoms cravings recommended doses remain high risk relapse even treated described one best current therapies taking look recommended dose range package insert upper limit recommended dose mg mg buprenorphine naloxone per day suboxone reported lack significant increase brain mu receptor occupancy doses mg mg implies little difference clinical effectiveness doses mg mg patients patient expresses need higher dose consider possible causes environmental stressors psychosocial issues increase cravings possible drug interactions increasing patient dose explore alternatives also consider possibility patient may exaggerating symptoms obtain additional medication diversion p recommended target dose mg buprenorphine mg naloxone per day clinical studies shown clinically effective dose although lower doses may effective patients patients mg dose alleviate withdrawal symptoms block attenuate effects opioid agonists least hours p clinical practice wide range effects buprenorphine doses fda approved considerations show subjectivity involved adjusting dose even understatement needs much greater investigation causes continued craving withdrawal symptoms patient taking recommended dose buprenorphine may genetically determined phenomenon either pharmacokinetic pharmacodynamic level partially accounted drug interactions investigation withdrawal symptoms continued craving passing concern potentially determines able remain maintenance therapy stay heroin important significant number patients actively treated psychiatric disorders antidepressants anxiolytics atypical antipsychotics mood stabilizers much medication use due inadequate treatment buprenorphine common symptoms insomnia anxiety depression associated opioid withdrawal complex clinical situations many patients life long history stress intolerance reluctance part clinicians especially mental health training explore treat problems patient indoctrinated idea maintenance medication going help stay heroin difficult transition say factors important need addressed especially true existing buprenorphine studies minimize counseling publicly presented counseling adds nothing results obtained buprenorphine finally large social media movement people want stop buprenorphine warning others behind widespread dissatisfaction needs done resolve overall impression issues paragraph leaves buprenorphine another heavily hyped medication live claims areas could use much clearer input nida additional scientific investigation additional studies drug interactions buprenorphine critically needed i use standard commercially available drug interaction software package time i enter psychiatric medication i get warning consider modify therapy list potential drug drug pharmacodynamic interactions cns level since high prevalence patients maintenance psychiatric medications represents deterrent physicians especially psychiatrists state unfavorable malpractice environment next issue determining susceptible opioid overuse dependence mind phenotype clear person takes first opioid tells me either fall love experienced intense euphoric almost hypomanic effect felt transformed medication person always wanted side effects modestly effective deterrents i told side effects complete lack analgesia acceptable order get intense euphoric high people identified authors discuss biomarkers pain pain relief single important biomarker would identify high risk group patients addiction currently commercial databases poll members various traits symptoms nih nida design polling questions look markers existing databases even marker identified simple strategy could used clinical practice could clinician tell patient self monitor intense euphoria report back physician soon possible occurs could patient told dispose pills bringing pharmacy euphoria thoughts dose escalation occur thoughts come mind might immediately useful would address limitations medication assisted treatment identifying risk population primary prevention opioid use problems george dawson md dfapa volkow nd collins fs role science addressing opioid crisis engl med may doi nejmsr epub ahead print pubmed pmid